2022
Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherence
2021
Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort
Fredericksen RJ, Whitney BM, Trejo E, Nance RM, Fitzsimmons E, Altice FL, Carrico AW, Cleland CM, Del Rio C, Duerr A, El-Sadr WM, Kahana S, Kuo I, Mayer K, Mehta S, Ouellet LJ, Quan VM, Rich J, Seal DW, Springer S, Taxman F, Wechsberg W, Crane HM, Delaney JAC. Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort. BMC Public Health 2021, 21: 2002. PMID: 34736425, PMCID: PMC8567631, DOI: 10.1186/s12889-021-12026-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultCondomsFemaleHeterosexualityHIV InfectionsHomosexuality, MaleHumansMaleRisk-TakingSexual BehaviorSexual PartnersSubstance-Related DisordersUnsafe SexConceptsLikelihood of CSRecent substance useHIV-negative partnersVaginal sexAnal sexSubstance useHIV-status unknown partnersMultivariable relative risk regressionExposure classificationType of sexHIV-negative adultsPooled effect estimatesPartner's HIV statusMulti-site cohortHigher likelihoodHeterosexual sexRelative risk regressionSingle substance usePoly-substance useHIV-negativeHIV statusRisk regressionPolysubstance useCannabis useSU exposure
2020
Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda
Springer SA, Barocas J, Wurcel A, Nijhawan A, Thakarar K, Lynfield R, Hurley H, Snowden J, Thornton A, del Rio C. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA’s Advocacy Agenda. The Journal Of Infectious Diseases 2020, 222: s230-s238. PMID: 32877568, PMCID: PMC7467230, DOI: 10.1093/infdis/jiz673.Peer-Reviewed Original ResearchMeSH KeywordsBacteremiaCommunicable Disease ControlFederal GovernmentHealth PolicyHepatitis BHepatitis CHIV InfectionsHuman RightsHumansIllicit DrugsInfectious Disease MedicineIntersectoral CollaborationInvasive Fungal InfectionsOpioid EpidemicPatient AdvocacyPreventive Health ServicesPublic Health AdministrationSocieties, MedicalState GovernmentSubstance-Related DisordersUnited StatesConceptsIllicit drug useInfectious diseasesAddiction specialistsDrug useSubstance use disorder treatmentUse disorder treatmentHarm reduction toolHIV physiciansInfectious complicationsEvidence-based practiceHIV epidemicOpioid epidemicCare continuumAssociated InfectionsTreatment servicesDisorder treatmentOpioid crisisDiseaseIDSAReview programEpidemicFurther disseminationHuman rights-based responseAdvocacy agendaMorbidityPreventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.Peer-Reviewed Original ResearchMeSH KeywordsContinuity of Patient CareDisease OutbreaksHIV InfectionsHumansPre-Exposure ProphylaxisSubstance Abuse, IntravenousSubstance-Related DisordersUnited StatesConceptsHIV outbreakRecent HIV outbreaksEpidemiology of HIVEvidence-based interventionsOpioid disordersHIV infectionTreatment cascadeEvidence-based responsesHIV epidemicOpioid epidemicHIV preventionPrescription opiatesHIVPWIDSynthetic opioidsDrugsPublic healthInfectionPreventionHigher proportionUnited StatesEpidemicOutbreakEditorial reviewRelentless cycleAddressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics
Springer SA, del Rio C. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. Infectious Disease Clinics Of North America 2020, 34: xiii-xiv. PMID: 32782107, PMCID: PMC7414777, DOI: 10.1016/j.idc.2020.06.016.Peer-Reviewed Original ResearchAnalgesics, OpioidCommunicable DiseasesEpidemicsHumansOpioid EpidemicOpioid-Related DisordersSubstance-Related Disorders
2019
Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases
Serota DP, Barocas JA, Springer SA. Infectious Complications of Addiction: A Call for a New Subspecialty Within Infectious Diseases. Clinical Infectious Diseases 2019, 70: 968-972. PMID: 31420651, PMCID: PMC7319263, DOI: 10.1093/cid/ciz804.Peer-Reviewed Original ResearchConceptsSubstance use disordersID physiciansHepatitis C virus infectionInfectious diseasesC virus infectionInfectious disease physiciansHuman immunodeficiency virusManagement of addictionComplex biopsychosocial factorsScope of practiceAddiction physiciansInfectious complicationsDisease physiciansImmunodeficiency virusInfectious consequencesVirus infectionClinical careUse disordersBiopsychosocial factorsHealth AdministrationInfectionSuccessful managementPhysiciansNew subspecialtyPotential rolePregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research?
Biondi BE, Frank C, Springer SA. Pregnancy, Substance Use, and Research: How do We Protect Women While Increasing Their Participation in Research? Journal Of Addiction Medicine 2019, 14: 182-184. PMID: 31403523, PMCID: PMC7059864, DOI: 10.1097/adm.0000000000000565.Peer-Reviewed Original ResearchMeSH KeywordsBehavioral ResearchBiomedical ResearchFemaleHumansPatient SelectionPregnancyPregnant WomenSubstance-Related DisordersWomen's HealthImpact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load
Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clinical Infectious Diseases 2019, 70: 867-874. PMID: 30994900, PMCID: PMC7319266, DOI: 10.1093/cid/ciz299.Peer-Reviewed Original ResearchMeSH KeywordsHIVHIV InfectionsHumansIllicit DrugsLongitudinal StudiesSubstance-Related DisordersViral LoadConceptsMethamphetamine/crystalViral suppressionViral loadIllicit opioidsIllicit drug useDrug useRelative viral loadHuman immunodeficiency virus (HIV) viral loadNumber of PLWHSubstance useHIV viral loadHuman immunodeficiency virusLongitudinal cohort studyHarm reduction interventionsCrystal useCocaine/crackHIV clinicCohort studyVL suppressionImmunodeficiency virusImpact of abstinenceClinical studiesHigher oddsDrug categoriesOpioids
2017
Cohort profile: seek, test, treat and retain United States criminal justice cohort
Chandler R, Gordon MS, Kruszka B, Strand LN, Altice FL, Beckwith CG, Biggs ML, Cunningham W, Chris Delaney JA, Flynn PM, Golin CE, Knight K, Kral AH, Kuo I, Lorvick J, Nance RM, Ouellet LJ, Rich JD, Sacks S, Seal D, Spaulding A, Springer SA, Taxman F, Wohl D, Young JD, Young R, Crane HM. Cohort profile: seek, test, treat and retain United States criminal justice cohort. Substance Abuse Treatment, Prevention, And Policy 2017, 12: 24. PMID: 28511680, PMCID: PMC5433052, DOI: 10.1186/s13011-017-0107-4.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsTreatment cascadeViral loadHIV RNA viral loadCD4 T-cell countRisk behaviorsSubstance useT-cell countsHepatitis C infectionRNA viral loadInjection drug useHealth Related QualityHIV treatment cascadeUnprotected sexual intercourseHealth care accessRecent polysubstance useC infectionViral suppressionHIV diagnosisHIV infectionMedian ageRelated qualityCriminal justice involvementART treatmentCohort members
2013
Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severity
2012
Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study
Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-Release Substance Abuse Outcomes Among HIV-Infected Jail Detainees: Results from a Multisite Study. AIDS And Behavior 2012, 17: 171-180. PMID: 23142854, PMCID: PMC3600070, DOI: 10.1007/s10461-012-0362-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior, AddictiveFemaleHealth Services AccessibilityHealth Services Needs and DemandHIV InfectionsHumansIll-Housed PersonsInsurance, HealthMaleMiddle AgedMultivariate AnalysisPatient DischargePrevalencePrisonsProspective StudiesSeverity of Illness IndexSocial WorkSocioeconomic FactorsSubstance-Related DisordersTreatment OutcomeYoung AdultConceptsOpioid useJail detaineesPoor health outcomesSubstance use disordersSubstance abuse outcomesSubsequent drug useSubstance abuse treatmentOpioid relapseProspective cohortPsychiatric morbidityAppropriate diagnosisHigh prevalenceComplicate treatmentPsychiatric careUse disordersAlcohol severitySix monthsHealth outcomesDrug useHIVHealthcare accessAbuse treatmentSubstance abuseDrug relapseHealthcare outcomes
2011
Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-HIV AgentsCase ManagementHIV InfectionsHumansMental DisordersPrisonersPrisonsPublic Health AdministrationRisk FactorsSubstance-Related DisordersUnited StatesConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insuranceSubstance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic
Meyer JP, Springer SA, Altice FL. Substance Abuse, Violence, and HIV in Women: A Literature Review of the Syndemic. Journal Of Women's Health 2011, 20: 991-1006. PMID: 21668380, PMCID: PMC3130513, DOI: 10.1089/jwh.2010.2328.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV/AIDSSubstance abuseHealthcare utilizationPoor HIV outcomesBetter health outcomesEvidence-based interventionsNegative health consequencesHIV outcomesHIV statusMedication adherenceHealth outcomesMental illnessHealth consequencesMental healthUrban womenWomenHIVBidirectional relationshipVulnerable groupsAIDSPrevention of violenceCurrent findingsAdherenceFuture studiesInconsistent definitions
2010
Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship
Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. AIDS And Behavior 2010, 14: 1213-1226. PMID: 20232242, PMCID: PMC2906682, DOI: 10.1007/s10461-010-9684-1.Peer-Reviewed Original ResearchMeSH KeywordsAntiretroviral Therapy, Highly ActiveCognition DisordersHIV InfectionsHumansMedication AdherenceRisk FactorsRisk-TakingSubstance-Related DisordersConceptsRisk reduction interventionsMedication adherenceCognitive impairmentRisk behaviorsHIV risk factorsHIV risk behaviorsImpact of HIVEffectiveness of interventionsSuboptimal adherenceRisk factorsNeurocognitive impairmentMental illnessCognitive functionSubstance abuseImpairmentAdherenceHIVInterventionReciprocal relationshipRiskSignificant barriersImproved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
Springer SA, Chen S, Altice FL. Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment. Journal Of Urban Health 2010, 87: 592-602. PMID: 20177974, PMCID: PMC2900572, DOI: 10.1007/s11524-010-9438-4.Peer-Reviewed Original ResearchConceptsOpioid agonist therapySubstance abuse treatment outcomesTreatment outcomesNon-detectable viral loadOpioid treatment outcomesBuprenorphine/naloxoneDSM-IV criteriaAgonist therapyAntiretroviral therapyCD4 countOpioid cravingAdverse eventsBuprenorphine treatmentOpioid dependenceViral loadUrine testingHIVTherapyVulnerable populationsWeeksOutcomesNLXTrialsInductionLikert scale
2009
Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsDirectly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean change
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical services